Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
This Healthcare Stock Is Soaring Following Exclusive License Agreement Announcement
Traders rushed to scoop up shares of %AclarisTherapeutics Inc. (Nasdaq: $ACRS), pushing the price of this small cap to close up at $4.59/share (+46.18%) on the day. This was a strong continuation of Monday’s success.
Aclaris Therapeutics Inc is a clinical-stage %Biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
MENAFN19112024007606016353ID1108904074
COMTEX_459989737/2604/2024-11-20T03:40:26